RMRita L. McGill

Rita L. McGill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rita L. McGill has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • R.J. Marcus

    6 shared publications
  • S.E. Sandroni

    4 shared publications
  • D.A. Healy

    Division of Nephrology and Hypertension, West Penn Allegheny Health System, Allegheny General Hospital Pittsburgh, Pennsylvania - USA

    3 shared publications
  • Stephen E. Sandroni

    Division of Nephrology and Hypertension, Allegheny General Hospital, West Penn Allegheny Health System, Pittsburgh, Pennsylvania - USA

    3 shared publications
  • B.C. Smith

    Division of Nephrology and Hypertension, West Penn Allegheny Health System, Allegheny General Hospital Pittsburgh, Pennsylvania - USA

    2 shared publications
  • D.J. Brouwer

    Division of Nephrology and Hypertension, West Penn Allegheny Health System, Allegheny General Hospital Pittsburgh, Pennsylvania - USA

    2 shared publications

Latest Publications

  • Anti-glomerular basement membrane disease treated with mycophenolate mofetil, corticosteroids, and plasmapheresis

    by Mari Mori, Uzoamaka Nwaogwugwu, Gwendolyn R. Akers, Rita L. McGill

    An 18-year-old woman presented with anemia, pulmonary hemorrhage, and necrotizing glomerulonephritis, and was diagnosed with anti-glomerular basement membrane (anti-GBM) disease. Treatment was undertaken with plasma exchange, mycophenolate mofetil and corticosteroids, due to patient refusal of cyclophosphamide. Clinical remission was successfully induced with this fertility-sparing regimen. A relapse due to therapy non-adherence was successfully treated with a second course of plasmapheresis, mycophenolate, and steroids. Thereafter, 6 months of directly observed therapy resulted in a favorable outcome with well-preserved pulmonary and renal function. This case suggests the possibility that mycophenolate may have a role in the treatment of anti-GBM disease.


  • Cardiac magnetic resonance imaging in hemodialysis patients

    by Rita L. McGill, Robert W.W. Biederman, Roger T. Getts, Shawn M. Hazlett, Sandeep B. Sharma, Jonathan Duran, Dana E. Brandys, Joshua C. Sysak, Kalathil K. Sureshkumar, Stephen E. Sandroni, et al.

    Background: The anatomy of left ventricular hypertro phy (LVH) in dialysis patients was studied with mag netic resonance imaging (MRI). Potential benefits of spironolactone were examined in a subset of patients. Methods:This was a prospective case series of 30 hemodialysis patients in whom cardiac MRI was per formed. Repeat MRI was done in a subset of 13 pa tients after 9 months of daily oral spironolactone 25 mg. Results:Subjects exhibited a characteristic cardiac morphology, distinct from both concentric LVH (cLVH) and eccentric LVH (eLVH). Compared with normal controls, LV mass index was increased, end-diastol ic volume index was increased, and ejection fraction was reduced, but sphericity indices did not differ. No significant changes were seen after spironolactone. Conclusions LVH in dialysis patients has a unique MRI appearance which is distinct from either cLVH or eLVH, with profound LV thickening and moderate dilation of the ventricular cavity. A 9-month course of spironolac tone therapy did not affect morphology.


  • Sorbent Hemodialysis: Clinical Experience With New Sorbent Cartridges and Hemodialyzers

    by Rita L. McGill, Jane R. Bakos, Tina Ko, Stephen E. Sandroni, Richard J. Marcus

    To recycle spent dialysate, a sorbent hemodialyzer uses a purification cartridge, adapted from water reclamation systems originally designed for the aerospace program. Increasing interest in home hemodialysis has driven a renewed examination of sorbent dialyzer technology, resulting in the development of a modern sorbent hemodialyzer and an array of new sorbent cartridges. Initial clinical experience with the Allient Hemodialysis System and the new sorbent cartridges is presented, with an emphasis on achievable clearances and ultrafiltration, as well as information about symptom profile and electrolyte balance.


  • Tissue plasminogen activator as a hemodialysis catheter locking solution

    by Rita L. McGILL, Joel A. Spero, Joshua C. Sysak, Stephen E. Sandroni, Richard J. Marcus

    Tunneled hemodialysis catheters require a "locking solution" between treatments to prevent catheter thrombosis. Heparin locks can be unsafe in patients with life-threatening bleeding diathesis because of unintentional anticoagulation. This study was designed to define the hematologic consequences of using tissue plasminogen activator (t-PA) as an alternative locking solution after heparin-free hemodialysis (HF-HD). Following HF-HD, t-PA 2 mg was instilled into each lumen of the dialysis catheter in 10 patients. Euglobulin clot lysis time (ECLT), fibrinogen, D-dimer, and fibrin degradation products were measured during the last hour of dialysis, and repeated 15 and 30 minutes after catheter locking. Dialysis catheter performance was reassessed at the time of the next hemodialysis. Fibrinogen, D-dimer, and fibrin degradation products were elevated at all time points, but did not change after t-PA. ECLT decreased significantly from baseline 15 minutes after catheter locking (217+/-64 vs. 132+/-75 min, p=0.016). ECLT values had returned to baseline (202+/-56 minutes) by 30 minutes. No episodes of bleeding or catheter thrombosis occurred, and catheter performance did not deteriorate. A 2 mg t-PA locking solution preserved dialysis catheter performance. ECLT decreased at 15 minutes, but normalized by 30 minutes, and did not enter the range in which bleeding would be likely. No clinical events were seen during this transient increase in systemic fibrinolysis.


    • 1 December 2007
      • Vol. 5  (2) , 664-9

    Steroid avoidance in renal transplant patients maintained on a cyclosporine-based protocol.

    by Tina Y Ko, Julie A Haddy, Richard J Marcus, Barbara J Carpenter, Dai D Nghiem, Rita L McGill, Stephen E Sandroni, Satish Patel, Molly Breckenridge, Kalathil K Sureshkumar

    The aim of this study was to analyze the effect of steroid avoidance, as compared with our pre-existing protocol that contained steroids, on renal allograft and patient survival. Secondary outcomes included body weight, diabetes, hyperlipidemia, and infection. This retrospective chart review of the results of steroid avoidance was performed in 169 patients who had undergone renal transplant between January 2000 and March 2002 and had received an immunosuppression regimen of cyclosporine, mycophenolate mofetil, and prednisone; and 148 patients who had undergone transplant between November 2002 and November 2004 who had received induction immunosuppression with a steroid taper by postoperative day 4 and were maintained on cyclosporine and mycophenolate mofetil. One-year allograft survival rates, rejection-free graft survival rates, and patient survival rates were 88%, 76%, and 97%, respectively, in the steroid-maintenance group compared with 90%, 74%, and 96%, respectively, in the steroid-avoidance group (P = NS). No differences were detected in multiple secondary variables related to the metabolic effects of steroid therapy. These data suggest that steroid avoidance can be performed safely and effectively in patients on a cyclosporine-based protocol of immunosuppression. Longer follow-ups are suggested to determine the effects of limited steroid exposure on the metabolic profiles of patients.


  • Safety of paracentesis in inpatients

    by P. Duggal, K.F. Farah, G. Anghel, R.J. Marcus, A.R. Lupetin, M.M. Babich, S.E. Sandroni, R.L. McGill

    Prior research has suggested that paracentesis is free from complications such as acute renal failure (ARF) providing albumin is administered. Actual safety of paracentesis > 1,000 ml was assessed at a tertiary care hospital. 300 inpatient paracenteses performed between 12/99 and 4/04 were identified by coding records, of which 40 procedures were excluded due to lack of pre- or post-procedure lab values. Charts were reviewed for serum creatinine (Scr) before and after procedures, ascites volume, and clinical outcomes. 44 deaths occurred after 260 paracenteses (16.9%). Among 33 patients with ARF, 13 (39.4%) died. Only 31/227 patients without ARF (13.7%) died (p < 0.001). Serum creatinine (Scr) > 1.6 mg/dl prior to paracentesis predicted a 22.5% rate of ARF, compared to 8% for Scr < 1.0 (p = 0.002). ARF increased as volume increased (9.9%, 12.4%, and 14.9%, for volumes of < 2,300, 2,300 - 3,200, and > 3,200 ml) but this trend did not have statistical significance (p = 0.426). ARF occurred in 11/69 (15.9%) of patients receiving albumin, compared to 22/191 (11.5%) of patients who did not (p = 0.462). Paracentesis in inpatients has significant rates of ARF and death. Scr > 1.6 prior to paracentesis predicts an increased rate of ARF. Development of ARF is associated with an increased rate of death. No advantage was demonstrated with administration of albumin. Pre- and post-paracentesis labwork should be routine in inpatients.


  • Open Access

    Reply

    by Robert W. W. Biederman, Richard J. Marcus, Rita L. McGill

  • Long-term outcomes of a fistula initiative: Sustaining “Fistula Culture”

    by R.L. Mcgill, R.J. Marcus, D.A. Healy, S. Nye, D.J. Brouwer, B.C. Smith, S.E. Sandroni

    From 1998 to 2003, a low cost fistula initiative at Allegheny General Hospital increased the rate of AV fistulas from 32% to 72%. We present an additional 25 months of vascular access data, with stratification of results by gender and long-term patient survival data. These data show the self-sustaining nature of ‘fistula culture’ in an urban hemodialysis unit, and the survival benefits that result from increased fistula rates.


  • Collateralization of the palmar arch by a failing radiocephalic fistula: An underappreciated complication of Cimino fistula anatomy

    by R.L. Mcgill, R.J. Marcus, D.A. Healy, P.M. Kiproff, S. Nye

    Stenosis at the anastomosis of an arteriovenous dialysis fistula can cause fistula failure due to venous thrombosis. Three cases are presented in which anastomotic stenosis in radiocephalic fistulas resulted in radial artery occlusion with collateralization of ulnar artery flow across the palmar arch. Hand ischemia did not occur, and reductions in fistula efficiency were clinically subtle. Urea kinetics were compromised, and a characteristic palmar bruit was heard.